Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT06015737




Registration number
NCT06015737
Ethics application status
Date submitted
1/08/2023
Date registered
29/08/2023
Date last updated
16/05/2024

Titles & IDs
Public title
A 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
Scientific title
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus Who Are Refractory and/or Intolerant to Antimalarial Therapy
Secondary ID [1] 0 0
2021-003698-70
Secondary ID [2] 0 0
D346BC00001
Universal Trial Number (UTN)
Trial acronym
LAVENDER
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cutaneous Lupus Erythematosus 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Combination Product - Anifrolumab
Other interventions - Placebo
Combination Product - Anifrolumab
Other interventions - Placebo

Experimental: Stage 1: Anifrolumab - The participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to and including week 51.

Placebo Comparator: Stage 1: Placebo - The participant will receive placebo as a SC injection from Week 0/Day 1 to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51.

Experimental: Stage 2: Anifrolumab - The participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to and including week 51.

Placebo Comparator: Stage 2: Placebo - The participant will receive placebo as a SC injection from Week 0/Day 1 to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51.


Combination Product: Anifrolumab
Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).

Other interventions: Placebo
Matching placebo solution for injection in aPFS.

Combination Product: Anifrolumab
Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).

Other interventions: Placebo
Matching placebo solution for injection in aPFS.
Intervention code [1] 0 0
Combination Product
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Stage 1 and Stage 2 (United States [US]): Number of participants with Cutaneous Lupus Activity of Investigator's Global Assessment-Revised (CLA-IGA-R) erythema score of 0 or 1 and at least a 2- point reduction relative to baseline
Timepoint [1] 0 0
At Week 24
Primary outcome [2] 0 0
Stage 1 and Stage 2 (European Union [EU]/Rest of the World [ROW]: Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score
Timepoint [2] 0 0
At Week 24
Secondary outcome [1] 0 0
Stage 1 and Stage 2 (US): Number of participants who achieve a CLA-IGA-R OMC score of 0 or 1 and at least a 1-point reduction relative to baseline
Timepoint [1] 0 0
At Week 24
Secondary outcome [2] 0 0
Stage 1 and Stage 2 (US): Number of participants who achieve a CLA-IGA-R OMC score of 0.
Timepoint [2] 0 0
At Week 24
Secondary outcome [3] 0 0
Stage 1 and Stage 2 (US): Number of participants with CLA-IGA-R follicular activity score of 0
Timepoint [3] 0 0
At Week 24
Secondary outcome [4] 0 0
Stage 1 and Stage 2 (EU/ROW): Percent change from baseline in total CLASI-A erythema score
Timepoint [4] 0 0
At Week 24
Secondary outcome [5] 0 0
Stage 1 and Stage 2 (EU/ROW): Percent change from baseline in total CLASI-A scale/hypertrophy score
Timepoint [5] 0 0
At Week 24
Secondary outcome [6] 0 0
Stage 1 and Stage 2 (US): Number of participants with CLA-IGA-R erythema score of 0 or 1 and at least a 2-point reduction relative to baseline, or a CLA-IGA-R OMC score of 0 or 1 and at least a 1-point reduction relative to baseline
Timepoint [6] 0 0
At Week 24
Secondary outcome [7] 0 0
Stage 1 and Stage 2 (US): Number of participants with CLA-IGA-R erythema score of 0 or 1 and at least a 2-point reduction relative to baseline
Timepoint [7] 0 0
At Week 12
Secondary outcome [8] 0 0
Stage 1 and Stage 2 (US): Number of participants with CLA-IGA-R OMC score of 0 or 1 and at least a 1-point reduction relative to baseline
Timepoint [8] 0 0
At Week 12
Secondary outcome [9] 0 0
Stage 1 and Stage 2 (EU/ROW): Number of participants with CLASI-70 response
Timepoint [9] 0 0
At Week 12
Secondary outcome [10] 0 0
Stage 1 and Stage 2 (US/EU/ROW): Change from baseline in Skindex-29+3 domain scores
Timepoint [10] 0 0
At Week 24
Secondary outcome [11] 0 0
Stage 1 and Stage 2 (US/EU/ROW): Serum trough (pre-dose) concentrations of anifrolumab
Timepoint [11] 0 0
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
Secondary outcome [12] 0 0
Stage 1 and Stage 2 (US/EU/ROW): Number of participants with positive antidrug antibody
Timepoint [12] 0 0
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
Secondary outcome [13] 0 0
Stage 1 and Stage 2 (US/EU/ROW): Percent change from baseline in suppression of the Interferon 21-gene
Timepoint [13] 0 0
Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
Secondary outcome [14] 0 0
Stage 2 (US/EU/ROW): Number of participants with = 7-point reduction from baseline in CLASI-A total score
Timepoint [14] 0 0
At Week 24
Secondary outcome [15] 0 0
Stage 2 (US): Number of participants who are CLA-IGA-R erythema responders from Week 24 up to and including Week 52
Timepoint [15] 0 0
Up to Week 52
Secondary outcome [16] 0 0
Stage 2 (EU): Number of participants who are CLASI-70 responders up to and including Week 52
Timepoint [16] 0 0
Up to Week 52

Eligibility
Key inclusion criteria
Key inclusion criteria:

- Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and
histologically confirmed with the following:

- CLASI-A total score = 10 points at Screening and confirmed at randomization.

- CLA-IGA-R erythema score of = 3 and CLA-IGA-R-OMC score of = 1 at Screening and
confirmed at randomization.

- Inadequate response or intolerant to antimalarial therapy.

- Participants should have no medical history or signs or symptoms of active or prior
tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest
CT scan result.

- Contraceptive use by males and females should be consistent with local regulations
regarding the methods of contraception for those participating in clinical studies.

- Participants should have a coronavirus disease 2019 (COVID-19) negative PCR or antigen
test result as per local policies at Screening.

Key exclusion criteria:

- History or evidence of suicidal ideation.

- Severe or life-threatening Systemic lupus erythematosus (SLE).

- Active SLE or Sjögren's Syndrome.

- Any active skin conditions other than CLE that may interfere with the study.

- History of recurrent infection requiring hospitalization and IV antibiotics.

- COVID-19 infection

- Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies.

- At screening, if participants do not meet the eligibility criteria assessed based on
laboratory test results e.g tests for total bilirubin, serum creatinine etc.

NOTE: Other protocol defined Inclusion/
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
17/06/2024
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
27/01/2028
Actual
Sample size
Target
460
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Box Hill
Recruitment hospital [2] 0 0
Research Site - Clayton
Recruitment hospital [3] 0 0
Research Site - Melbourne
Recruitment hospital [4] 0 0
Research Site - Westmead
Recruitment hospital [5] 0 0
Research Site - Woolloongabba
Recruitment postcode(s) [1] 0 0
3128 - Box Hill
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
3004 - Melbourne
Recruitment postcode(s) [4] 0 0
2145 - Westmead
Recruitment postcode(s) [5] 0 0
04102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
Oregon
Country [10] 0 0
United States of America
State/province [10] 0 0
Virginia
Country [11] 0 0
Argentina
State/province [11] 0 0
Ciudad de Buenos Aires
Country [12] 0 0
Argentina
State/province [12] 0 0
Córdoba
Country [13] 0 0
Argentina
State/province [13] 0 0
Quilmes
Country [14] 0 0
Austria
State/province [14] 0 0
Graz
Country [15] 0 0
Austria
State/province [15] 0 0
Innsbruck
Country [16] 0 0
Austria
State/province [16] 0 0
Linz
Country [17] 0 0
Austria
State/province [17] 0 0
Sankt Pölten
Country [18] 0 0
Belgium
State/province [18] 0 0
Liège
Country [19] 0 0
Brazil
State/province [19] 0 0
Belo Horizonte
Country [20] 0 0
Brazil
State/province [20] 0 0
Porto Alegre
Country [21] 0 0
Brazil
State/province [21] 0 0
Salvador
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Sofia
Country [23] 0 0
Chile
State/province [23] 0 0
Santiago
Country [24] 0 0
China
State/province [24] 0 0
Baotou
Country [25] 0 0
China
State/province [25] 0 0
Beijing
Country [26] 0 0
China
State/province [26] 0 0
Changchun
Country [27] 0 0
China
State/province [27] 0 0
Chengdu
Country [28] 0 0
China
State/province [28] 0 0
Chongqing
Country [29] 0 0
China
State/province [29] 0 0
Guangzhou
Country [30] 0 0
China
State/province [30] 0 0
Hangzhou
Country [31] 0 0
China
State/province [31] 0 0
Heilongjiang
Country [32] 0 0
China
State/province [32] 0 0
Jinan
Country [33] 0 0
China
State/province [33] 0 0
Kunming
Country [34] 0 0
China
State/province [34] 0 0
Nanchang
Country [35] 0 0
China
State/province [35] 0 0
Nanjing
Country [36] 0 0
China
State/province [36] 0 0
Shanghai
Country [37] 0 0
China
State/province [37] 0 0
Shenzhen
Country [38] 0 0
China
State/province [38] 0 0
Shijiazhuang
Country [39] 0 0
China
State/province [39] 0 0
Wuhan
Country [40] 0 0
Colombia
State/province [40] 0 0
Barranquilla
Country [41] 0 0
Colombia
State/province [41] 0 0
Bogota
Country [42] 0 0
Colombia
State/province [42] 0 0
Chia
Country [43] 0 0
Denmark
State/province [43] 0 0
København
Country [44] 0 0
France
State/province [44] 0 0
Bois Guillaume
Country [45] 0 0
France
State/province [45] 0 0
Chambray Les Tours
Country [46] 0 0
France
State/province [46] 0 0
Lille Cedex
Country [47] 0 0
France
State/province [47] 0 0
Lyon Cedex 03
Country [48] 0 0
France
State/province [48] 0 0
Nice
Country [49] 0 0
France
State/province [49] 0 0
Paris
Country [50] 0 0
France
State/province [50] 0 0
Toulouse Cedex 9
Country [51] 0 0
Germany
State/province [51] 0 0
Berlin
Country [52] 0 0
Germany
State/province [52] 0 0
Bochum
Country [53] 0 0
Germany
State/province [53] 0 0
Dresden
Country [54] 0 0
Germany
State/province [54] 0 0
Hannover
Country [55] 0 0
Germany
State/province [55] 0 0
Kiel
Country [56] 0 0
Germany
State/province [56] 0 0
Leipzig
Country [57] 0 0
Germany
State/province [57] 0 0
Mainz
Country [58] 0 0
Germany
State/province [58] 0 0
Regensburg
Country [59] 0 0
Germany
State/province [59] 0 0
Wuppertal
Country [60] 0 0
Greece
State/province [60] 0 0
Athens
Country [61] 0 0
Italy
State/province [61] 0 0
Brescia
Country [62] 0 0
Italy
State/province [62] 0 0
Florence
Country [63] 0 0
Italy
State/province [63] 0 0
Napoli
Country [64] 0 0
Italy
State/province [64] 0 0
Rome
Country [65] 0 0
Italy
State/province [65] 0 0
Torrette
Country [66] 0 0
Japan
State/province [66] 0 0
Fukuoka-Shi
Country [67] 0 0
Korea, Republic of
State/province [67] 0 0
Seoul
Country [68] 0 0
Mexico
State/province [68] 0 0
Guadalajara
Country [69] 0 0
Netherlands
State/province [69] 0 0
Rotterdam
Country [70] 0 0
Philippines
State/province [70] 0 0
Iloilo City
Country [71] 0 0
Philippines
State/province [71] 0 0
Lipa
Country [72] 0 0
Philippines
State/province [72] 0 0
Manila
Country [73] 0 0
Poland
State/province [73] 0 0
Katowice
Country [74] 0 0
Poland
State/province [74] 0 0
Olsztyn
Country [75] 0 0
Poland
State/province [75] 0 0
Poznan
Country [76] 0 0
Poland
State/province [76] 0 0
Warszawa
Country [77] 0 0
Serbia
State/province [77] 0 0
Kragujevac
Country [78] 0 0
South Africa
State/province [78] 0 0
Cape Town
Country [79] 0 0
South Africa
State/province [79] 0 0
Johannesburg
Country [80] 0 0
Spain
State/province [80] 0 0
Barcelona
Country [81] 0 0
Spain
State/province [81] 0 0
Madrid
Country [82] 0 0
Taiwan
State/province [82] 0 0
Kaohsiung
Country [83] 0 0
Taiwan
State/province [83] 0 0
Taichung
Country [84] 0 0
United Kingdom
State/province [84] 0 0
Cambridge
Country [85] 0 0
United Kingdom
State/province [85] 0 0
Leeds
Country [86] 0 0
United Kingdom
State/province [86] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AstraZeneca
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Parexel
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus
placebo in adult participants with cutaneous lupus erythematosus (CLE).
Trial website
https://clinicaltrials.gov/ct2/show/NCT06015737
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
AstraZeneca Clinical Study Information Center
Address 0 0
Country 0 0
Phone 0 0
1-877-240-9479
Fax 0 0
Email 0 0
information.center@astrazeneca.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT06015737